Approved for use through 04/30/2003. OMB 0651-0032 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

<u> </u>	* -		_
Application Number	09/845,570	RECE	IVED
Filing Date	April 30, 2001		
First Named Inventor	Jo Seongbong	AUG 2	9 2003
Art Unit	1653		
Examiner Name	L. Mayes	TECH CENTER	1600/2900
Attorney Docket Number	1789-03805		1000/2000

ENCLOSURES (check all that apply)						
Fee Transmittal Form	☐ Drawing(s)	After Allowance Communication to Group				
☐ Fee Attached	☐ Licensing-related Papers ☐ Petition	Appeal Communication to Board of Appeals and Interferences				
Amendment/Reply	Petition					
After Final	Petition to Convert to a Provisional Application	Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)				
Affidavits/declaration(s)	Power of Attorney, Revocation	☐ Proprietary Information				
Extension of Time Request	Change of Correspondence Address	☐ Status Letter				
Express Abandonment Request	☐ Terminal Disclaimer	☐ Other Enclosure(s) (please				
☐ Information Disclosure Statement	Request for Refund	identify below):				
☐ Certified Copy of Priority Document	S) CD, Number of CD(s)	Copy of Notice to Comply (2 p.) and Diskette				
Response to Missing Parts/ Incomplete Application						
Response to Missing Parts under 37 CFR 1.52 or 1.53	Remarks					
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT						
Firm Or ADELE C. NOON Individual Name						
Signature	al Noon					
Date July 8	03					
CERTIFICATE OF MAILING						
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Gommissioner for Patents. P. O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.						
Typed or Printed Name M. A. CRABTREE						
Signature	Jac Craphy Date	July <u>&</u> , 2003				

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P. O. Box 1450. Alexandria. VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, p. o. Box 1450, Alexandria, VA 22313-1450.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS:

Jo Seongbong and

Antonios G. Mikos

GROUP ART UNIT: 1653

SERIAL NO .:

09/845,570

EXAMINER:

RECEIVED

L. Mayes

AUG 2 9 2003

April 30, 2001

88888

§

§

Biocompatible Macromers

TECH CENTER 1600/2900

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Attn: Christopher S.F. Low, SPE U.S. Patent and Trademark Office Box Sequence, Room 1B03-Mailroom Crystal Plaza Two 2011 South Clark Place Arlington, VA 22202

Atty. Dkt. No. 1789-03805

Date: July 8, 2003

Sir:

Applicants acknowledge receipt of the Office Communication dated July 1, 2003, that the computer readable form that was filed April 8, 2003 with this application was found to be damaged and/or unreadable as indicated on the CFR Diskette Problem Report.

In the Office Communication dated November 19, 2002, the Examiner requested that Applicant provide an initial or substitute computer readable form (CRF) copy of the "Sequence Listing". A substitute computer readable form (CRF) copy of the "Sequence Listing" is also enclosed.

Applicants have also attached a copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosure as required by the Examiner.

A Statement Under 37 CFR § 1.821(e)-(g) is also enclosed.